Q3 EPS Estimate for Harmony Biosciences Boosted by Analyst

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Harmony Biosciences in a report released on Thursday, September 25th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.97 per share for the quarter, up from their prior forecast of $0.83. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ FY2025 earnings at $3.68 EPS, Q1 2026 earnings at $0.89 EPS, Q4 2026 earnings at $1.53 EPS, FY2026 earnings at $4.82 EPS and FY2027 earnings at $5.63 EPS.

A number of other research firms have also commented on HRMY. Wall Street Zen lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Sunday. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a report on Thursday. Oppenheimer began coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 target price for the company. Needham & Company LLC cut their target price on shares of Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, September 24th. Finally, The Goldman Sachs Group began coverage on shares of Harmony Biosciences in a research note on Thursday, July 10th. They set a “neutral” rating and a $33.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Harmony Biosciences has a consensus rating of “Buy” and an average target price of $45.50.

Harmony Biosciences Trading Up 1.7%

NASDAQ:HRMY opened at $27.51 on Monday. The company has a fifty day moving average of $34.92 and a 200 day moving average of $33.37. Harmony Biosciences has a 52 week low of $26.35 and a 52 week high of $41.61. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $1.58 billion, a P/E ratio of 8.87, a P/E/G ratio of 0.34 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The firm had revenue of $200.49 million for the quarter, compared to the consensus estimate of $204.37 million. During the same quarter in the prior year, the company earned $1.05 earnings per share. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. Harmony Biosciences has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds have recently bought and sold shares of HRMY. Boston Partners bought a new stake in Harmony Biosciences during the second quarter worth about $19,398,000. Arrowstreet Capital Limited Partnership boosted its stake in Harmony Biosciences by 127.6% during the second quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after acquiring an additional 508,498 shares in the last quarter. New Vernon Capital Holdings II LLC boosted its stake in Harmony Biosciences by 3,219.0% during the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock worth $16,211,000 after acquiring an additional 473,708 shares in the last quarter. Nomura Holdings Inc. boosted its stake in Harmony Biosciences by 382.3% during the second quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock worth $13,364,000 after acquiring an additional 335,237 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Harmony Biosciences by 36.3% during the second quarter. Marshall Wace LLP now owns 1,209,484 shares of the company’s stock worth $38,220,000 after acquiring an additional 321,947 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.